Correlation Between Inhibikase Therapeutics and RAPT Therapeutics
Can any of the company-specific risk be diversified away by investing in both Inhibikase Therapeutics and RAPT Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inhibikase Therapeutics and RAPT Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Inhibikase Therapeutics and RAPT Therapeutics, you can compare the effects of market volatilities on Inhibikase Therapeutics and RAPT Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inhibikase Therapeutics with a short position of RAPT Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inhibikase Therapeutics and RAPT Therapeutics.
Diversification Opportunities for Inhibikase Therapeutics and RAPT Therapeutics
-0.05 | Correlation Coefficient |
Good diversification
The 3 months correlation between Inhibikase and RAPT is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Inhibikase Therapeutics and RAPT Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on RAPT Therapeutics and Inhibikase Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inhibikase Therapeutics are associated (or correlated) with RAPT Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of RAPT Therapeutics has no effect on the direction of Inhibikase Therapeutics i.e., Inhibikase Therapeutics and RAPT Therapeutics go up and down completely randomly.
Pair Corralation between Inhibikase Therapeutics and RAPT Therapeutics
Considering the 90-day investment horizon Inhibikase Therapeutics is expected to generate 0.62 times more return on investment than RAPT Therapeutics. However, Inhibikase Therapeutics is 1.61 times less risky than RAPT Therapeutics. It trades about 0.07 of its potential returns per unit of risk. RAPT Therapeutics is currently generating about -0.21 per unit of risk. If you would invest 261.00 in Inhibikase Therapeutics on September 4, 2024 and sell it today you would earn a total of 15.00 from holding Inhibikase Therapeutics or generate 5.75% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Inhibikase Therapeutics vs. RAPT Therapeutics
Performance |
| Timeline |
| Inhibikase Therapeutics |
| RAPT Therapeutics |
Inhibikase Therapeutics and RAPT Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Inhibikase Therapeutics and RAPT Therapeutics
The main advantage of trading using opposite Inhibikase Therapeutics and RAPT Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inhibikase Therapeutics position performs unexpectedly, RAPT Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in RAPT Therapeutics will offset losses from the drop in RAPT Therapeutics' long position.| Inhibikase Therapeutics vs. Candel Therapeutics | Inhibikase Therapeutics vs. Cingulate Warrants | Inhibikase Therapeutics vs. Unicycive Therapeutics | Inhibikase Therapeutics vs. Cardio Diagnostics Holdings |
| RAPT Therapeutics vs. Connect Biopharma Holdings | RAPT Therapeutics vs. Tyra Biosciences | RAPT Therapeutics vs. Xilio Development | RAPT Therapeutics vs. Mineralys Therapeutics, Common |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Complementary Tools
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |